Wei Xiaoying, Wang Hong, Liu Huiquan, Wang Jianguo, Zhou Peijie, Li Xiaoyang, He Yuan, Li Yan, Han Dong, Mei Ting, Wang Yuwen, Li Ziye, Ning Junhao, Xu Zilong, Wang Anlin, Li Yixuan, Cheng Jingjing, Qian Dong
Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
J Immunother Cancer. 2025 Jan 7;13(1):e009993. doi: 10.1136/jitc-2024-009993.
Immunosuppressive phenotype compromised immunotherapy efficacy of hepatocellular carcinoma. Tumor cells intrinsic mitochondria dynamics could pass effects on the extracellular microenvironment through mtDNA stress. PGAM5 anchors at mitochondria and regulates mitochondria functions. We aim to explore whether the regulation of tumor-intrinsic PGAM5 on mitochondria affects tumor-infiltrating immune cells in the microenvironment and whether tumor-intrinsic PGAM5 can be a therapeutic target to enhance the immunotherapy efficacy of hepatocellular carcinoma (HCC).
We analyzed the correlation of PGAM5 expression and immune cells infiltration using Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data sets based on cibersort algorithm and tumor-tissue arrays from two independent cohorts. To further validate our findings, we established subcutaneous and orthotopic mouse HCC models with tumor-intrinsic Pgam5 deficiency and analyzed tumor-infiltrating immune cells by flow cytometry and single-cell RNA sequencing. Mechanistically, we established an in vitro co-culture system and analyzed proteomics data to find out the bridge between tumor cell PGAM5 and tumor-associated macrophages (TAMs) in the microenvironment. Immunofluorescence, chromatin-immunoprecipitation, ELISA, mass spectrometry were conducted to explore the molecular pathway. Macrophages were depleted to investigate whether the effects of tumor-intrinsic PGAM5 on TAMs could affect immunotherapy efficacy in HCC orthotopic and subcutaneous mouse models.
PGAM5 expression in tumor was positively correlated with M2-phenotype TAM infiltration in patients with both HCC and mouse HCC tumor models. High tumor-intrinsic PGAM5 expression promoting M2 TAMs infiltration correlated with poor clinical-pathological characteristics and prognosis in patients with HCC. Disruption of tumor-intrinsic Pgam5 reduced TAM M2 polarization and inhibited HCC tumor growth in tumor-bearing mice. Mechanistically, in HCC cells PGAM5 deficiency inhibited mitochondria fission by promoting TRIM28 binding with DRP1, which increased ubiquitination and degradation of DRP1. Tumor-intrinsic PGAM5 deficiency mediated mitochondria fusion and reduced cytosolic mtDNA stress which attenuated TLR9 activation and downstream NF-κB-regulated CCL2 secretion. Furthermore, disruption of tumor-intrinsic Pgam5 significantly facilitated CD8 T cells activation and improved anti-programmed cell death protein-1 therapeutic efficacy with macrophages depletion compromising synergistic antitumor immune response.
Our results shed light on the effect of tumor mitochondria dynamics on TAMs in tumor microenvironment. Tumor-intrinsic PGAM5 can be a therapeutic target to improve immunotherapy efficacy in patients with HCC.
免疫抑制表型会削弱肝细胞癌免疫治疗的疗效。肿瘤细胞内在的线粒体动力学可通过线粒体DNA应激对细胞外微环境产生影响。PGAM5定位于线粒体并调节线粒体功能。我们旨在探讨肿瘤内在的PGAM5对线粒体的调控是否会影响微环境中肿瘤浸润免疫细胞,以及肿瘤内在的PGAM5是否可作为增强肝细胞癌(HCC)免疫治疗疗效的治疗靶点。
我们使用基因表达综合数据库(GEO)和癌症基因组图谱肝细胞癌(TCGA-LIHC)数据集,基于cibersort算法以及来自两个独立队列的肿瘤组织芯片,分析PGAM5表达与免疫细胞浸润的相关性。为进一步验证我们的发现,我们建立了肿瘤内在Pgam5缺陷的皮下和原位小鼠HCC模型,并通过流式细胞术和单细胞RNA测序分析肿瘤浸润免疫细胞。从机制上讲,我们建立了体外共培养系统并分析蛋白质组学数据,以找出肿瘤细胞PGAM5与微环境中肿瘤相关巨噬细胞(TAM)之间的联系。进行免疫荧光、染色质免疫沉淀、酶联免疫吸附测定、质谱分析以探索分子途径。去除巨噬细胞以研究肿瘤内在PGAM5对TAM细胞的影响是否会影响HCC原位和皮下小鼠模型的免疫治疗疗效。
在HCC患者和小鼠HCC肿瘤模型中,肿瘤中PGAM5的表达与M2表型TAM浸润呈正相关。肿瘤内在PGAM5高表达促进M2 TAM浸润与HCC患者不良的临床病理特征和预后相关。破坏肿瘤内在的Pgam5可减少TAM的M2极化,并抑制荷瘤小鼠的HCC肿瘤生长。从机制上讲,在HCC细胞中,PGAM5缺陷通过促进TRIM28与DRP1结合来抑制线粒体分裂,从而增加DRP1的泛素化和降解。肿瘤内在的PGAM5缺陷介导线粒体融合并减少细胞质线粒体DNA应激,从而减弱TLR9激活和下游NF-κB调节的CCL2分泌。此外,破坏肿瘤内在的Pgam5可显著促进CD8 T细胞活化,并提高抗程序性细胞死亡蛋白1的治疗效果,去除巨噬细胞会损害协同抗肿瘤免疫反应。
我们的结果揭示了肿瘤线粒体动力学对肿瘤微环境中TAM的影响。肿瘤内在的PGAM5可作为提高HCC患者免疫治疗疗效的治疗靶点。